#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

5 years ago
R&D
Cell/Gene Tx

A mi­cro-cap with a po­ten­tial­ly promis­ing coro­n­avirus drug en­lists mask-skep­tic con­gress­man for DSMB

5 years ago
People
Coronavirus

News brief­ing: Com­pa­ny de­vel­op­ing 'mag­ic mush­room' treat­ment hits Nas­daq; Spring­Works en­ters spon­sored re­search ...

5 years ago
News Briefing

Seat­tle-based Athi­ra, aim­ing for tough Alzheimer's and Parkin­son's tar­gets, rais­es $204M for IPO

5 years ago
Financing

Seat­tle Ge­net­ic­s' Astel­las-part­nered ADC nails con­fir­ma­to­ry PhI­II in urothe­lial can­cer

5 years ago
R&D
Pharma

Vedan­ta Bio­sciences taps Big Phar­ma vet Jef­frey Sil­ber as CMO; Robert Doe­bele leaves be­hind teach­ing post at Col­orado ...

5 years ago
Peer Review

#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve ...

5 years ago
R&D

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col ...

5 years ago
R&D
Coronavirus

Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose ...

5 years ago
Coronavirus

Roche says a sec­ond tri­al of Actem­ra re­vives hopes for IL-6. What now?

5 years ago
Coronavirus

Stronger to­geth­er? Boehringer and Mi­rati team to put first KRAS-KRAS com­bo in the clin­ic

5 years ago
Deals

#ES­MO20: Re­gen­eron, Sanofi eye an­oth­er first for their PD-1 con­tender Lib­tayo with promis­ing da­ta for on­col­o­gy niche

5 years ago
R&D

News brief­ing: Check­point reads out new in­ter­im mC­SCC da­ta; Taysha eyes $125M for its flash IPO

5 years ago
News Briefing

A long­time Cy­tomX ex­ec re-emerges at Syn­thekine, an $82M Stan­ford spin­out

5 years ago
People
Financing

One month af­ter $115M megaround, mus­cle dis­ease-fo­cused Dyne goes pub­lic with $233M IPO

5 years ago
Financing

Sean Bo­hen's break from bio­phar­ma is over. The ex-As­traZeneca CMO has re­tired his Big Phar­ma jer­sey and is now — ...

5 years ago
People
Bioregnum

Af­ter lead­ing Cel­gene buy­out, Matthew Ro­den leaves Bris­tol My­ers Squibb for ven­ture cap­i­tal firm

5 years ago
People

Covid-19 roundup: Amid calls for trans­paren­cy, Mod­er­na re­leas­es full PhI­II pro­to­col; As­traZeneca tri­al halt thought ...

5 years ago
Coronavirus

Past a turn­ing point, Finch scores $90M to com­plete the fi­nal stretch for oral mi­cro­bio­me ther­a­py

5 years ago
Financing

Sarep­ta faces an­oth­er gene ther­a­py hic­cup as Re­genxbio sues over Jim Wilson's patent

5 years ago
Cell/Gene Tx

'The biggest in­flec­tion point ever': On R&D day, Mod­er­na CEO Stéphane Ban­cel dou­bles down on vac­cines and lays out a ...

5 years ago
R&D

Jim Brod­er­ick reels in a $100M Se­ries B to ex­plore a 'new and big' an­gle of im­mune reg­u­la­tion

5 years ago
Financing

La­va breaks pro­longed si­lence with an $83M Se­ries C and two I/O pro­grams set for the clin­ic

5 years ago
Startups
R&D

Mod­er­na picks up a $75M cash wind­fall as long­time col­lab­o­ra­tor Ver­tex signs up for a gene edit­ing as­sault on cys­tic ...

5 years ago
Deals
Cell/Gene Tx
First page Previous page 800801802803804805806 Next page Last page
A service from the Financial Times